Inactive Instrument

Standard BioTools Inc.

Equities

SLGC

US83444K1051

Biotechnology & Medical Research

SomaLogic, Inc. Provides Revenue Guidance for the Full Year 2022

May 12, 2022 at 06:35 pm EDT

SomaLogic, Inc. provided revenue guidance for the full year 2022. The company is maintaining revenue guidance for the full year 2022 at a range of $105 million to $110 million, which represents 29% to 35% growth over the company's 2021 revenue.

Latest news about Standard BioTools Inc.

Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P Global BMI Index	Jan. 10	CI
Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P TMI Index	Jan. 10	CI
Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023	Jan. 08	CI
Declaration of Voting Results by SomaLogic Inc	Jan. 05	CI
Declaration of Voting Results by SomaLogic Inc	Jan. 05	CI
Declaration of Voting Results by SomaLogic Inc	Jan. 05	CI
Declaration of Voting Results by SomaLogic Inc	Jan. 05	CI
Declaration of Voting Results by SomaLogic Inc	Jan. 05	CI
Standard BioTools Says Merger With SomaLogic Completed	Jan. 05	MT
SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger	Jan. 05	MT
SomaLogic, Inc.(NasdaqGM:SLGC) dropped from NASDAQ Composite Index	Jan. 05	CI
Madryn Asset Addresses SomaLogic?s Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools	Jan. 04	CI
Madryn Asset Management, LP Sends an Email to Stockholders in Connection with Somalogic, Inc.?s Special Meeting of Stockholders	Jan. 04	CI
Madryn Asset Management Sent a Letter to the Delaware Court of Chancery	Jan. 03	CI
Madryn Asset Provides Information to the Shareholders	Jan. 03	CI
Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools	Jan. 03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	Jan. 03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	Jan. 03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	Jan. 03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	Jan. 03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	Jan. 03	CI
SomaLogic Sends an Open Letter to Shareholders	Jan. 02	CI
SomaLogic Sends an Open Letter to Shareholders	Jan. 02	CI
SomaLogic Sends an Open Letter to Shareholders	Jan. 02	CI
SomaLogic Sends an Open Letter to Shareholders	Jan. 02	CI

Chart Standard BioTools Inc.

Duration

Period

More charts

Company Profile

SomaLogic, Inc. is a commercial-stage proteomics company. The Company has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. It offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+32.03%	50.85B
IQVIA HOLDINGS INC.	+0.87%	42.82B
LONZA GROUP AG	+48.88%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.95%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-22.09%	19.13B
BIO-TECHNE CORPORATION	+8.06%	13.05B
MEDPACE HOLDINGS, INC.	+26.62%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.33%	12.08B

Other Biotechnology & Medical Research